SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 196.3 CNY | +0.52% |
|
-2.35% | +50.73% |
| May. 15 | Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Cash Dividend for 2023, Payable May 22, 2024 | CI |
| Apr. 26 | Shenyang Xingqi Pharmaceutical's Q1 Profit Jumps 80% | MT |
| Sales 2024 * | 2.12B 292M | Sales 2025 * | 2.68B 370M | Capitalization | 34.24B 4.73B |
|---|---|---|---|---|---|
| Net income 2024 * | 449M 62.01M | Net income 2025 * | 669M 92.39M | EV / Sales 2024 * | 16.2 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 12.8 x |
| P/E ratio 2024 * |
76.3
x | P/E ratio 2025 * |
51.2
x | Employees | 1,995 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 47.12% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.52% | ||
| 1 week | -2.35% | ||
| Current month | +5.87% | ||
| 1 month | +26.65% | ||
| 3 months | +81.26% | ||
| 6 months | +83.21% | ||
| Current year | +50.73% |
1 week
190.98
202.14
1 month
163.57214.28
Current year
92.86214.28
1 year
80.17214.28
3 years
40.05214.28
5 years
23.76214.28
10 years
3.16214.28
| Managers | Title | Age | Since |
|---|---|---|---|
E Gao
CEO | Chief Executive Officer | 50 | 00-07-04 |
| 37 | - | ||
Ya Nan Cheng
DFI | Director of Finance/CFO | 50 | 02-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiao Yan Kong
BRD | Director/Board Member | 51 | Jan. 04 |
Ji Dong Liu
CHM | Chairman | 67 | 00-07-04 |
E Gao
CEO | Chief Executive Officer | 50 | 00-07-04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.43% | 12 M€ | -16.71% | - | |
| 0.00% | 34 M€ | +4.01% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-22 | 196.3 | +0.52% | 2 184 030 |
| 24-05-22 | 195.3 | -2.41% | 2,613,033 |
| 24-05-21 | 200.1 | -0.42% | 1,851,891 |
| 24-05-20 | 200.9 | +1.80% | 2,415,388 |
| 24-05-17 | 197.4 | -1.31% | 4,512,582 |
End-of-day quote Shenzhen S.E., May 22, 2024
More quotes
SHENYANG XINGQI PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of ophthalmic drugs. The Companyâs main products are ophthalmic prescription drugs, including corneal repairing drugs, anti-bacteria drugs, artificial tears, anti-inflammation drugs, anti-allergic drugs, as well as anti-hyperemia & fatigue relief drugs and others. The Company mainly distributes its products within domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
196.3
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +50.73% | 4.7B | |
| +9.28% | 8.74B | |
| -15.14% | 4.94B | |
| +4.36% | 3.98B | |
| -26.13% | 2.28B | |
| +12.07% | 2.28B | |
| +16.45% | 2.14B | |
| -33.59% | 2.12B | |
| -0.50% | 1.64B | |
| -4.35% | 1.53B |
- Stock Market
- Equities
- 300573 Stock
